Intellia Therapeutics (NTLA) Stock Overview
A clinical-stage gene editing company, focuses on the development of curative genome editing treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NTLA Community Fair Values
Create NarrativeSee what 86 others think this stock is worth. Follow their fair value or set your own to get alerts.
Intellia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.93 |
| 52 Week High | US$26.99 |
| 52 Week Low | US$5.90 |
| Beta | 2.38 |
| 1 Month Change | 111.33% |
| 3 Month Change | 115.01% |
| 1 Year Change | 23.59% |
| 3 Year Change | -47.50% |
| 5 Year Change | 4.51% |
| Change since IPO | 17.33% |
Recent News & Updates
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
Sep 19Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Sep 18
Recent updates
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
Sep 19Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Sep 18Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) First-Quarter Report
May 11Industry Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 10
Phase III Trials And Gene Editing Will Bring Promising Therapies
Strategic discontinuation of less promising programs and capital prioritization are expected to improve net margins and enhance commercial prospects.Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress
Mar 02Earnings Release: Here's Why Analysts Cut Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target To US$46.08
Mar 02Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
Feb 15Intellia Therapeutics: Buying The Path To Commercialization
Jan 13Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 19Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Nov 11Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story
Nov 05Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Oct 25Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Shareholder Returns
| NTLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.8% | 0.9% | -1.2% |
| 1Y | 23.6% | -0.6% | 15.1% |
Return vs Industry: NTLA exceeded the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: NTLA exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| NTLA volatility | |
|---|---|
| NTLA Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTLA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NTLA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 403 | John Leonard | www.intelliatx.com |
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
Intellia Therapeutics, Inc. Fundamentals Summary
| NTLA fundamental statistics | |
|---|---|
| Market cap | US$2.78b |
| Earnings (TTM) | -US$480.19m |
| Revenue (TTM) | US$52.86m |
Is NTLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTLA income statement (TTM) | |
|---|---|
| Revenue | US$52.86m |
| Cost of Revenue | US$440.10m |
| Gross Profit | -US$387.25m |
| Other Expenses | US$92.95m |
| Earnings | -US$480.19m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.47 |
| Gross Margin | -732.63% |
| Net Profit Margin | -908.48% |
| Debt/Equity Ratio | 0% |
How did NTLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 18:04 |
| End of Day Share Price | 2025/10/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intellia Therapeutics, Inc. is covered by 39 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jack Allen | Baird |
| Huidong Wang | Barclays |